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Chondrosarcoma, a primary malignancy of bone, has eluded successful treatment with modern chemotherapeutic and radiation
regimens. To date, surgical resection of these tumors remains the only curative treatment oﬀered to patients with this diagnosis.
Understanding and exploring the nature of chemotherapy and radiation resistance in chondrosarcoma could lead to new
molecular targets and more directed therapy for these notoriously diﬃcult-to-treat tumors. Here we review the most current
hypotheses regarding the molecular mechanisms mediating chemotherapy and radiation resistance and the future direction of
chondrosarcoma therapy research.
1. “Know thy Enemy”: Treatment Obstacles in
Patientswith Chondrosarcoma
Tzu,the6thcenturyBCChinesewartheorist,ismostfamous
for his military treatise The Art of War and for having
written, “Know thyself, know thy enemy; one thousand
battles, one thousand victories” [1]. Chondrosarcoma, a
heterogeneous group of tumors with extraordinarily diverse
presentations and morphologies that have an enormous
range of clinical behaviors, is a complex and diﬃcult enemy
to know. To date, patients who receive a diagnosis of
chondrosarcoma are treated primarily with wide resective
surgery since these tumors are notoriously resistant to both
chemotherapy and radiation treatment. Dramatic excisions
and even amputations are required, since local control of
tumorisofparamountimportanceinordertopreventfuture
metastasis.
Chondrosarcoma is the second most common type
of primary bone malignancy in the United States after
osteosarcoma. It represents 26% of all primary bone cancers,
with approximately 2000 new cases every year [2]. These
tumors are characterized by cartilage-forming cells with no
evidence of direct osteoid formation [3]a n da r eg r a d e d
based on local invasiveness and metastatic potential. They
can be further classiﬁed by histologic characteristics such
as cellularity, matrix changes, cell character, and replicative
activity [4]. Clinically, the most common sites of tumor
formation include the pelvis and appendicular long bones,
though reports in the literature have documented other sites
includingthedistalappendicularbones,temporomandibular
region [5], and thoracic spine [6].
While wide resection with limb salvage surgery or ampu-
tation are deﬁnitive therapies for patients presenting with
appendicular tumors [7], such surgeries introduce disability
and morbidity into the lives of patients. Furthermore, suﬃ-
ciently wide resection is not always possible in large tumors,
tumors growing in the pelvis or axial skeleton, or tumors
thathavealreadymetastasized.Insuchcases,tumorlocation,
chemoresistance,andradioresistanceleadtoinsurmountable
treatment obstacles and very poor outcomes. Understanding
the molecular mechanisms of resistance to chemotherapy
and radiation in these tumors could lead to new targets2 Sarcoma
for treatment or adjuvant therapies to surgery, thereby
improving the length and quality of life in patients suﬀering
from chondrosarcoma.
In this paper, we will provide a summary of the most
recent research regarding the molecular pathways and genes
responsible for chemotherapy and radiation resistance in
chondrosarcoma tumors (see Table 1). We will also explore
the implications of these molecular mechanisms with respect
to their role in the development of new therapies for this
diﬃcult-to-treat cancer.
2. The Expression of P-Glycoprotein
AllowsChondrosarcoma Cellsto
Withstandthe CytotoxicEffects of
Most Chemotherapy Agents
P-glycoprotein is an ATP-dependent membrane-bound
pump that excretes small hydrophobic molecules and is
normally expressed in cells with secretory functions such as
the proximal tubular cells of the kidney and the epithelial
lining of the bile duct. It is also expressed in the hypertrophic
region of the epiphyseal growth plate, providing additional
evidence for its important physiologic excretory rolein
protecting the cell from extracellular insults [8].
The expression of P-glycoprotein in chondrosarcoma
tumors has been well-established, and it has been proposed
that this expression is an extremely important mechanism
in the development of chemoresistance (see Figure 1).
P-glycoprotein is encoded by the gene Multiple Drug
Resistance-1, or MDR-1. Expression of this protein is com-
moninbothbenignandmalignantcartilaginouslesions,and
in one study, 90% of tumors stained with speciﬁc antibodies
were positive for P-glycoprotein expression [9]. The authors
postulated that MDR-1 expression was a marker for the
presence of drug resistance to multiple chemotherapy agents
including cyclophosphamide, doxorubicin, vincristine, cis-
platin, methotrexate, and dacarbazine.
It has been shown using ﬂuorescence microscopy and
other in vitro techniques that chondrosarcomacells express-
ing P-glycoprotein accumulate lower levels of intracellular
doxorubicin thanchondrosarcoma cells that do not express
P-glycoprotein, and that the P-glycoprotein-positive cells
are insensitive to the cytotoxic eﬀects of doxorubicin at
physiologic concentrations in vitro [10]. Rosier et al. have
postulated that the development of chemoresistantchon-
drosarcoma tumors is a result of selective pressure against P-
glycoprotein-negativecellsinthepresenceofcytotoxicagents
[8]. Alternatively, some authors suggest that toxin exposure
causes direct upregulation of P-glycoprotein expression [13].
More recently, the importance of P-glycoprotein in
mediating chemoresistance has been highlighted through
experiments in which P-glycoprotein was inhibited both
pharmacologically and with gene silencing techniques. Using
siRNA, Kim et al. showed that knocking down the expression
of MDR-1 increased chemosensitivity by up to 4.1 fold
[12]. Of note, a combination of the inhibition of P-
glycoproteinwiththeinhibitionoftheantiapoptoticproteins
Bcl-2, Bcl-xL, and XIAP showed an even higher increase
in chemosensitivity, up to 5.5 fold [12]. These ﬁndings
suggest that though P-glycoprotein is clearly an important
mediator of chemoresistance in chondrosarcoma cells; other
mechanisms are also involved.
3. Telomerase ActivityMediates
Chondrosarcoma CellImmortality
DNA polymerase cannot faithfully complete replication to
the end of the superstructure of the macromolecule, which
leads to the loss of nucleotides with each replication cycle—
thisisknownasthe“endreplicationproblem.”Telomeresare
regions of noncoding DNA at the end of the double strand
that protect coding regions from this degradation. With
every newgeneration, a piece of the telomere is lost, even-
tually causing the cell to exit the replication cycle [14]. Germ
cells express telomerase, an enzyme capable of synthesizing
new telomeres via its own RNA template, thereby allowing
telomeres to be faithfully replicated and preventing the cell
from exiting the replication cycle. Many cancer cell types
including testicular, ovarian, breast, endometrial, and basal
cell carcinoma and lymphoma express telomerase, and this is
one suggested mechanism of attaining cellular immortality
[15].
Many chondrosarcoma cells also express telomerase,
and it has been established that telomerase expression in
chondrosarcoma correlates signiﬁcantly with tumor grade
and rates of recurrence. Martin et al. have proposed that
using immunohistochemical techniques to identify those
tumors that express telomerase could be a useful adjuvant
to traditional prognostic grading systems [16]. Dr. Martin’s
group has also explored the role of telomerase combined
with the loss of tumor suppressor protein p16 as a means of
malignant transformation of cartilage neoplasms and found
that these two mutations in combination lead to a more
aggressive and invasive phenotype in vitro [17].
Because of the important relationship between telom-
erase expression and cancer cell immortality, inhibition of
telomerase has been an expanding area of cancer therapy
research. It is hypothesized that by preventing the continued
elongation of telomeres, malignant cells can reenter the
normal cell cycleand and undergo the normal genetic and
molecular checks on replication. Additionally, these cells
would become susceptible to the apoptotic mechanisms that
normallyexecutetheprocessofprogrammedcelldeathwhen
genetic damage is induced by chemotherapeutic agents.
The speciﬁc pharmacologic inhibitor of telomerase,
BIBR1532, has been tested as a means to resensitize chon-
drosarcoma cells to traditional modes of chemotherapy.
Parsch et al. have established telomerase expression in the
chondrosarcoma cell line SW1353 and used the TRAP assay
to show that BIBR1532 inhibits telomerase in SW1353 cells.
Furthermore, it was demonstrated that long-term dosage
of the telomerase inhibitor slowed the rate of growth
of SW1353 cells, but did not arrest growth completely;
the authors contend that this incomplete growth arrest is
caused by chemotherapy-induced natural selection of clonesSarcoma 3
Table 1: A summary of the mechanisms involved in chemotherapy and radiation resistance in chondrosarcoma cells. Summarized here
are the various molecular mechanisms responsible chemotherapy and radiation resistance in chondrosarcoma, strategies to overcome these
mechanisms, and the results of studies testing these strategies as possible adjuvants to traditional surgical treatments. See text for more
in-depth discussions of each topic.
Resistance
mechanism Eﬀect within the cell Therapeutic strategies Has treatment been tested?
P-glycoprotein
expression
Exports chemotherapy
drugs from within the
cell
Gene silencing using siRNA pharmacologic
inhibition using C-4
In vitro: dramatic increases in
chemosensitivity
Telomerase
activity “Immortal” cell
phenotype
BIBR1532- pharmacological telomerase
inhibitor
BIBR152- in vitro:s l o w e dg r o w t h
and increased sensitivity to
cisplatin.
GRN 163L- pharmacological telomerase
inhibitor
GRN 163L- in vivo: but not in
chondrosarcoma—helpful
addition in leukemia treatment
Angiogenesis Supports larger tumors,
allows metastasis
SU6668-inhibits receptors for VEGF, FGF,
PDGF ET-743 and plasminogen-related
protein B-chemotherapeutic and
endothelial-cell-metabolism downregulator
In vivo murine model: decreased
tumor size, vascularization.
In vivo murine model:induction
of profound necrosis, inhibition
of neovascularization
COX-2
expression
Unclear, but associated
with poor prognosis
COX-2 inhibitors-mechanism of action
remains unclear
In vivo: slows cancer growth,
although growth relapses after
six weeks of treatment
Melovonate
synthesis
Shift bone remodeling
balance toward
resorption
Bisphosphonates-inhibit melovonate
synthesis in the bone microenvironment
In vivo: induction of apoptosis,
inhibition of metalloproteinase
activity, and reduction of VEGF
levels
Tumor
Suppressor p16
Mutation
Decreased tendency
toward apoptosis
p16-restoring virusOncolytic
viruses-selectively target immune-inducing
molecules to cells with pathway defects
In vitro: increased
radiosensitivity in p16-deﬁcient
cells.
In vivo, but not in
chondrosarcoma-results show
strong selectivity, desired
eﬃcacy, no serious side eﬀects.
Increased
expression of
Bcl-2, Bcl-xL, and
XIAP
Decreased tendency
toward apoptosis
Downregulation via
pharmacotherapy/siRNA-shift cellular
balance toward apoptosis
In vitro: increased
radiosensitivity
In vivo: increased
chemosensitivity
Hypoxia Decreased ROS creation
by radiation Acridine orange-enhances ROS creation In vivo: signiﬁcantly increased
radiosensitivity
with strong telomerase activity. Moreover, data from this
study show that cell lines with low-telomerase activity were
more sensitive to cisplatin-induced apoptosis while cell lines
with high levels of telomerase activity were nearly resistant
[18].
In clinical trials, telomerase inhibition by the speciﬁc
inhibitor GRN 163L has been shown to have additive or
even synergistic eﬀects when used in combination with other
chemotherapies and radiation regimens against leukemia
[19]. These promising clinical results taken together with
the aforementioned in vitro studies suggest that telomerase
inhibition may be a beneﬁcial strategy in the treatment of
chemoresistant chondrosarcoma.
4.TargetingAngiogenesisin
Chondrosarcoma Slows Tumor Growth
One important area of cancer research has been the role
of angiogenesis in tumor growth and metastasis. As tumors
grow beyond a few millimeters in size, oxygen can no
longer diﬀu s et oe v e r yc e l l ,a n dt h et u m o rb e c o m e sh y p o x i c .
Angiogenesis, or the growth of new blood vessels, must
o c c u rf o rt h et u m o rt og r o wb e y o n dac e r t a i ns i z e .H y p o x i a
induces angiogenesis via increased levels of the transcription
factor hypoxia inducible factor-1α (HIF-1α). This small
moleculeactivates the transcription of several proangiogenic
factors, the most important of which is the cytokine vascular4 Sarcoma
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Mediated by
Tumor suppressors
Chemotherapy
Radiation
P-glycoprotein
Repair mechanisms fail, but...
Survival
Mediated by
p16inactivating mutations
Chondrosarcoma cell
Normal cell
Proapoptotic proteins
Antiapoptotic proteins
O2
￿−
Figure 1: An overview of how chondrosarcoma cells evade the cytotoxic eﬀects of chemotherapy and radiation. In normal cells, radiation
and chemotherapy cause cell death by inducing genetic damage either directly, or in the case of radiation, through a reactive oxygen species
(ROS) intermediate. For example, the drug doxorubicin intercalates with DNA, preventing replication, while ROS cause strand breaks. This
damage is sensed by the cell, and then through the actions of tumor suppressor proteins such as p16 or p53 and the proapoptotic proteins
including Bax, Bak, and Bim, the cell undergoes apoptosis, becomes senescent, or necroses. The chondrosarcoma cell’s main defense against
chemotherapeutic agents is P-glycoprotein, a membrane-bound pump that extrudes small, hydrophobic molecules from within the cell
[10]. The action of P-glycoprotein can lower intracellular concentrations of chemotherapeutic agents beyond a point at which they exact
their cytotoxic eﬀects. Though radiation treatment still induces genetic damage in chondrosarcoma cells, several mutations allow them to
survive. These mutations include inactivation of the gene encoding the important tumor suppressor p16 via methylation or deletion [11],
and upregulation of the antiapoptotic proteins Bcl-2 and XIAP [12]. Figure adapted from Motifolio Cell and Nucleic Acid Toolkit.
endothelial growth factor (VEGF). Because tumors depend
onangiogenesisforsurvivalandfurthergrowth,thispathway
has become a popular drug target in many cancers, and
chondrosarcoma is no exception.
Immunostaining and siRNA experiments have been used
to demonstrate that chondrosarcoma tumors of all grades
expressHIF-1αathigherlevelsthandonormalchondrocytes
and benign cartilaginous tumors [20], and that VEGF
expression is dependent on HIF-1α [21]. Another study
concluded that in chondrosarcoma, HIF-1α expression was
only present in 40% of tumors sampled; however, this study
was unique in staining for nuclear HIF-1α, the active form.
Tumors positive for nuclear HIF-1α were associated with
decreased disease-free survival, suggesting that nuclear HIF-
1α could serve as a prognostic factor in addition to histologic
grade [20].
In terms of therapeutic potential, inhibiting angiogenesis
may be a promising strategy for inducing growth arrest as
an adjuvant to surgical removal of chondrosarcoma tumors.
Klenke et al. have demonstrated that inhibition of the angio-
genic tyrosine kinase receptors for VEGF, ﬁbroblast growth
factor (FGF), and platelet-derived growth factor (PDGF)
with the small-molecule inhibitor SU6668 has a beneﬁcial
eﬀect on tumor size and neovascular density in vivo. In this
study, mice with chondrosarcoma xenografts implanted in
the calvarium and treated with SU6668 had tumors that
were 53% smaller than those tumors in mice treated with
control injections at the end of the 28 day growth period.
Additionally, tumors in mice treated with the inhibitor had
vessel densities reduced by 37% compared to untreated mice
[22]. In another in vivo xenograft model, ecteinascidin-743
(ET-743), a sea squirt-derived chemotherapeutic, elicited
profound tumor necrosis and prevented neovascularization
whenusedincombinationwithplasminogen-relatedprotein
B, an endogenous molecule that downregulates endothelial
cell metabolism [23].
5. Beyond Traditional Chemotherapy:
AlternativeDrugTargetsin
Chemoresistant Chondrosarcoma
Though they present unique treatment obstacles, chon-
drosarcoma tumors also present unique treatment oppor-
tunities because they maintain many of the phenotypic
characteristics of the chondrocytes from which they areSarcoma 5
derived. One interesting area of research involves treating
these phenotypic similarities as drug targets. Some exciting
examples of these targets include cyclooxygenase-2 (COX-2)
expression, melovonate synthesis, and estrogen signaling.
Chondrocytes are known to express the inﬂammatory
cytokine COX-2 when exposed to other inﬂammatory
cytokines and free radicals [24]. COX-2 expression has been
demonstrated in peripheral chondrosarcoma tumors in
several studies, and higher levels of expression are associated
withpoorprognosis[25,26].Schrageetal.hypothesizedthat
there may be a role for COX-2 inhibition in chondrosarcoma
treatment. Dr. Schrage demonstrated that the COX-2
inhibitor Celecoxib decreased cell viability in vitro. Celecoxib
slowed tumor growth in vivo initially. Interestingly, these
mechanisms were independent of COX-2 activity since
several cell lines showed these responses but did not express
COX-2 according to ELISA assays [25]. Further study is
needed in this area because the in vivo growth arrest relapsed
after six weeks of treatment.
Like Celecoxib, bisphosphonates are typically used in the
treatment of other musculoskeletal conditions, but may have
indications in the treatment of chondrosarcoma. Bispho-
sphonates inhibit melovonate synthesis and are extremely
speciﬁc to the bone microenvironment. The mechanism of
action involves inhibiting osteoclast-mediated bone resorp-
tion and the promotion of osteoblast diﬀerentiation. Inter-
estingly, bisphosphonates may have an anticancer eﬀect
by inducing apoptosis, inhibiting metalloproteinase activity,
and reducing VEGF levels [27]. It has been shown that
the bisphosphonate zoledronic acid acts synergistically with
paclitaxel in osteosarcomas [28]. In the context of chon-
drosarcoma, one case report demonstrates that zoledronic
acidsigniﬁcantlyreducesbonepainandimprovesthequality
of life of patients with chondrosarcoma and chordoma [29].
Furthermore,anotherstudyshowedthatthethirdgeneration
bisphosphonateminodronatedecreaseschondrosarcomacell
growth in a dose-dependent manner in vitro [30].
Finally, the role of estrogen signaling in skeletal devel-
opment has implications for chondrosarcoma treatment.
Estrogen signaling is involved in longitudinal bone growth,
chondrocyte diﬀerentiation, and epiphyseal growth plate
maturation. Therefore, Cleton-Jansen et al. hypothesized
that targeting estrogen signaling could inhibit chondrosar-
comacell proliferation. Dr. Cleton-Jansen demonstrated that
inhibiting estrogen signaling with the aromatase inhibitor
exemestane inhibits chondrosarcoma cell growth in vitro
[31]. Estrogen signaling has been an important target in
other cancers such as breast carcinoma, and this study
suggests that it may also be an important target in chon-
drosarcoma.
6. RadiationResistanceinChondrosarcoma
Radiation treatment is used widely and commonly in cancer
therapy and incites its cytotoxic eﬀects via the production
of reactive oxygen species (ROS). These ROS then cause
strand breaks in DNA. Under normal physiologic condi-
tions, healthy cells have DNA repair machinery that senses
ROS-induced genetic damage and initiates attempts to repair
this damage (see Figure 1). If the damage is irreparable,
proteins called tumor suppressors will signal to the cell to
stop dividing and the cell will either undergo apoptosis,
necrose, or become senescent. These mechanisms prevent
genetic damage from being passed to future generations.
The eﬃcacy of radiation treatment is contingent upon
several things: ﬁrst, formation of ROS is necessary to
mediate genetic damage; second, the genetic damage-sensing
mechanisms must be intact; third, the tumor suppression
activity of the cell must be functional. Radiation resistance in
tumor cells could feasibly develop at any one of these three
steps due to mutations in the myriad proteins involved in
these complex cascades. The exact mechanisms of radiation
resistance in chondrosarcoma have remained somewhat
unclear, though several culprits, which will be reviewed here,
have been identiﬁed.
7. Loss of Tumor Suppressor
p16 in Chondrosarcoma Leads to
Radioresistance
The role of the loss of tumor suppressor genes is one well-
known cause of radioresistance in numerous tumors. In
chondrosarcoma, it has been shown that genetic changes
to the p16 coding gene CDKN2 are quite common in
high-grade tumors. Asp et al. have shown using PCR
and gene sequencing that 41% of chondrosarcoma tumors
sampled had some sort of change to CDKN2, while no
tumors sampled had any change to the well-known p53
tumor suppressor gene [11]. In addition, almost all of
the highly malignant tumors sampled had alterations to
this gene, suggesting that changes to the CDKN2 gene are
one important mechanism contributing to high malignancy.
Such mutations to p16 are not seen in benign cartilaginous
tumors such as enchondroma, suggesting a role for this
gene in the transition to an aggressive, malignant phenotype
[32]. These ﬁndings support evidence linking altered p16
expression to malignant phenotypes in other types of cancer
including breast carcinoma and oropharyngeal squamous
cell carcinoma [33, 34].
The role of p16 in mediating radioresistance was demon-
strated by experiments that showed that reintroducing p16
expression with a viral vector can increase radiosensitivity
in vitro by inciting mitotic catastrophe [35]. While no
method of restoring the functionality of the p16 pathway
has been developed in vivo, research is underway to use the
defective p16/retinoblastoma (RB) pathway as the marker
for targeting viral vectors to cancer cells. A virus could
theoretically be derived that would only infect cells with a
defect in the pathway; alternatively, a virus could be designed
that would infect indiscriminately but would only replicate
and/or produce its immune-modulatory product in tumor
cells [36].
Of course, treatments using viral vectors present their
own issues such as ensuring viral genomic stability and selec-
tivity for cancer cells versus healthy cells. Early trials of the
use of such an oncolytic virus in the treatment of many types6 Sarcoma
of cancer are currently underway. This particular adenovirus
selectively targets cells with p16/RB pathway dysfunction
and stimulates the production of granulocyte-macrophage
colony-stimulatingfactor(GM-CSF),animmunemodulator
that locally induces CD8+ T cell and natural killer (NK)
cell activity. Though the initial results suggest that the virus
is capable of increasing tumor chemosensitivity without
causing severe side eﬀects, these trials have not included
chondrosarcoma patients [37].
8.The AntiapoptoticProteins
Bcl-2, Bcl-xL, andXIAP CanMediate
Radioresistance
Within any cell, survival and proliferation are mediated by
a delicate balance between pro- and antiapoptotic signals.
When the balance is tipped in favor of antiapoptotic signals,
mediated by proteins such as Bcl-2, Bcl-xL, and XIAP, the
cell will survive, proliferate, diﬀerentiate, and migrate. Con-
versely, when the balance is tipped in favor of proapoptotic
signals, such as Bax, Bak, and Bim, the cell will exit the cell
cycle, disrupt its nucleus, and begin to break apart into small
parts commonly referred to as “blebs.”
Given that ionizing radiation causes cytotoxicity by
inducing apoptosis, one theory regarding radiation resis-
tance is that some cancer cells may tip their own internal
balance to favor the anti-apoptosis signals. That way, no
matter how much genetic damage is induced by radiation,
the cell will continue to diﬀerentiate, divide, and survive.
Kim et al. have shown that chondrosarcoma cells express
higher basal levels of the antiapoptotic proteins Bcl-2 and
XIAP than do normal chondrocytes in vitro, though the
two cell types express similar amounts of the antiapoptotic
protein Bcl-xL [38]. In addition, radiation induces increased
expression of these proteins in a dose-dependent manner,
suggesting an important role of antiapoptotic signaling
in radioresistance [38]. Finally, Dr. Kim demonstrated an
increase in radiosensitivity by using siRNA to silence the
expression of these proteins—silencing them individually
could lead to up to 9.2 fold increases in radiation sensitivity.
Silencing two of these genes simultaneously enhanced sensi-
tivity to 5 and 10 Gy doses of radiation by 11.3 and 11.2 fold,
respectively [38].
Clinically, gene silencing of Bcl-2 has great poten-
tial as an adjuvant therapy. In Phase III trials, it has
already been shown that the antisense oligonucleotide
G3139 combined with the chemotherapy agent dacarbazine
increased progression-free and overall survival in patients
withadvancedmelanomawhencomparedtopatientstreated
with just dacarbazine alone [39]. Such clinical studies have
shown that treating humans with antisense oligonucleotides
against Bcl-2 is feasible and potentially beneﬁcial.
Little is known about the possible additive or synergistic
eﬀects of Bcl-2 antisense oligonucleotides in the context
of radiation treatment, as no clinical trials have been
undertaken. Several studies have shown promising results
in xenograft models: Bcl-2 antisense oligonucleotides have
inherent antitumor activity and can enhance the eﬀects of
local tumor irradiation in a colon carcinoma model [40]a n d
in a nasopharyngeal carcinoma model [41].
Given these ﬁndings, it would appear that targeting the
expressionoftheseantiapoptotic proteinsisapromisingnew
avenue of inducing radiation sensitivity in chondrosarcoma
tumors. Previous clinical studies have already established the
feasibility and safety of antisense oligonucleotide treatment
and pharmacologic inhibition in humans, though in vivo
studies in a chondrosarcoma model are lacking.
9.Technological Advances
in Radiation Therapy: Improving
Outcomes in Chondrosarcoma
Many improvements in the ﬁeld of radiation oncology in
general can be applied to treatment of chondrosarcoma. In
short, these advances can be classiﬁed into those that allow
thedeliveryofgreateramountsofradiationtothetumorand
those that enhance the killing power of a given amount of
radiation. With regardto the formercategory, improvements
in proton therapy have allowed the safe delivery of more
radiation to tumors. Unlike traditional radiotherapy, proton
therapydoesnotdeliverradiationtotissuebeyondthetumor
[42]. This is especially important in tumors occurring in
areas such as the spine and the skull (tumors which are
traditionally very diﬃcult to resect with a wide margin
and, as such, most often in need of radiation). Additional
advances in this technology have allowed increased focusing
of the radiation (“spot-scanning” technology), allowing the
use of more intense radiation without increasing the toxicity
to the patients. This technology was recently tested in
chondrosarcomaof the skull base, and the results suggest
that the technique is relatively safe and can be an eﬀective
adjuvant to surgery when used at high doses [43].
In addition to delivering more radiation directly to
tumors, improving the eﬃciency of a given dose of radiation
is another strategy for dealing with radioresistant tumors.
Because of the hypoxic conditions inherent to the microen-
vironment of a chondrosarcoma tumor, the generation
of ROS is severely curtailed. Acridine Orange (AO) is
capable of producing damaging oxidants in the presence of
gamma radiation even in oxygen-poor environments. This
capability makes AO an attractive addition to radiotherapy
for chondrosarcoma. Moussavi-Harami et al. have shown
that AO in and of itself is only slightly cytotoxic but induces
signiﬁcant increases in sensitivity to low-dose radiation in
vitro [35].
10. Conclusion
We have reviewed here the numerous mechanisms that
make chondrosarcoma a challenging cancer to treat. As
Tzu suggested, knowing the enemy is a vital part of any
successful confrontation. Clinical experience has shown us
that chondrosarcoma is strongly resistant to traditional
means of cancer treatment, save for dramatic surgeries. Yet
Tzualsonotesthat“thewaytoavoidwhatisstrongistostrike
at what is weak” [1]. Cutting edge research in the ﬁeld ofSarcoma 7
chondrosarcoma has exposed some of these key weaknesses.
Exploiting these vulnerabilities will allow us to undermine
the resistance that has made these tumors such a frustrating
clinical entity and to oﬀermuchneeded treatmentoptions to
patients who would otherwise face a very poor prognosis.
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